Author Affiliation: Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison.
Contempo Updates Section Editor: Janet M.
Torpy, MD, Contributing Editor.
Age-related macular degeneration (AMD), the leading cause of legal blindness
in people 65 years or older in the United States,1 is
a degenerative disorder of the retinal pigment epithelium (RPE) and neurosensory
retina. The macula is the portion of the central retina with the greatest
concentration of photoreceptors and provides high-resolution visual acuity.
The early stages of AMD are characterized clinically by the development of
soft drusen associated with pigmentary abnormalities of the RPE and retina
(Figure 1A). Drusen, accumulations
of amorphous, acellular debris within the basement membrane of the RPE, are
seen ophthalmoscopically as yellow spots within the macula.2 While
small drusen are commonly present in the macula as a consequence of aging,
the presence of large and numerous drusen is associated with AMD.3 Late-stage AMD is characterized by the development
of well-defined areas of RPE loss (geographic atrophy) (Figure 1B), choroidal neovascularization (CNV) (Figure 1C), pigment epithelial detachment, and fibrous scarring
of the macula (disciform scarring).2,4 The
presence of soft drusen, pigmentary abnormalities, and geographic atrophy
is commonly termed dry (nonneovascular) AMD. The development of CNV, pigment
epithelial detachment, or disciform scarring is an exudative process and commonly
termed wet (neovascular) AMD. The wet form of AMD comprises approximately
15% of the cases,5 but because of its severity,
accounts for the majority of severe visual loss due to AMD.6
Gottlieb JL. Age-Related Macular Degeneration. JAMA. 2002;288(18):2233–2236. doi:10.1001/jama.288.18.2233
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: